XBIO
XBIO
NASDAQ · Biotechnology

Xenetic Biosciences Inc

$1.66
-0.21 (-11.05%)
Financial Highlights (FY 2026)
Revenue
4.23M
Net Income
-3,812,462
Gross Margin
97.9%
Profit Margin
-90.1%
Rev Growth
+20.3%
D/E Ratio
—
Revenue & Net Income
Margin Trends
FY 2026 FY 2025 FY 2024 FY 2023
Gross Margin 97.9% 97.9% 44.0% 44.0%
Operating Margin -95.2% -85.7% -30.8% -29.4%
Profit Margin -90.1% -85.6% -29.9% -25.1%
Income Statement
FY 2026 FY 2025 FY 2024 FY 2023
Revenue 4.23M 3.52M 899.1K 945.5K
Gross Profit 4.14M 3.44M 395.9K 416.3K
Operating Income -4,030,884 -3,015,874 -277,010 -277,924
Net Income -3,812,462 -2,852,453 -268,437 -236,795
Gross Margin 97.9% 97.9% 44.0% 44.0%
Operating Margin -95.2% -85.7% -30.8% -29.4%
Profit Margin -90.1% -85.6% -29.9% -25.1%
Rev Growth +20.3% +20.3% -1.1% +22.5%
Balance Sheet
FY 2026 FY 2025 FY 2024 FY 2023
Total Debt 0 0 814.0K 797.5K
Total Equity — — 2.89M 2.95M
D/E Ratio — — 0.28 0.27
Cash Flow
FY 2026 FY 2025 FY 2024 FY 2023
EBITDA -4,031,216 -3,183,685 -429,552 -415,366
Free Cash Flow — — -251,567 -250,593